(MedPage Today) — CHICAGO — A once-weekly basal insulin had similar safety and efficacy to a daily insulin option, a series of trials from the phase III QWINT development program found.
In QWINT-1, there was a similar HbA1c reduction with…
Source link : https://www.medpagetoday.com/meetingcoverage/ada/116189
Author :
Publish date : 2025-06-22 19:56:00
Copyright for syndicated content belongs to the linked Source.
